Top 5 NASDAQ Genetics Stocks Updated January 2025 INN

Trust me — you’ll want to read this report before putting another dollar into any tech stock. But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible. In fact, Verge argues this company’s supercheap AI technology should concern rivals.

• Beam Therapeutics utilizes CRISPR technology to replace specific bases in the genome utilizing a method known as base editing, which only breaks one DNA molecule and may enhance cell survival rates.
• She believes the market is changing and that early adopters will benefit from the convergence of genomics and AI.
• In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.
• I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.
• NTLA’s lead in vivo product candidates are nex-z for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of HAE.

Which company dominates the next-generation sequencing market?

According to clinical data, at least one in six people have a variant spelling an underlying health condition. Consequently, the testing services market will be over $17 billion by 2026. CRISPR Therapeutics and its big partner, Vertex Pharmaceuticals (VRTX +0.72%), became the first to win regulatory approval for a CRISPR gene-editing therapy in December 2023 for Casgevy in treating sickle cell disease.

• The two companies are evaluating nexiguran ziclumeran (also known as NTLA-2001) in a phase 3 clinical study for the treatment of transthyretin amyloidosis (ATTR) with cardiomyopathy, a rare genetic disease.
• Shares in Avidity reached a yearly peak of US$52.50 on November 13, a day after the company introduced its first two precision cardiology development candidates targeting the root cause of genetic diseases of the heart.
• The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications.
• This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

NASDAQ: CRBU

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from genomics stocks these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Another breakthrough is the development of genome editing approaches, such as CRISPR/Cas9 technology. Gene editing companies, such as BEAM Therapeutics (BEAM Quick QuoteBEAM – Free Report) and CRISPR Therapeutics AG (CRSP Quick QuoteCRSP – Free Report) , hold potential to treat and cure diseases caused by genetic variants. As the name suggests, they make changes or correct defects in the organism’s DNA.

Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

The primary focus is to evaluate all the genes of an organism rather than individual genes. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

Top 5 NASDAQ Genetics Stocks (Updated January

Fulgent’s revenue growth has reflected the COVID-19 pandemic, with an increase in 2022 as testing ramped up and a slower pace of growth in 2022 as schools and government organizations reopened. This company’s rapidly growing stock market for genetic testing for children’s disorders. Management predicts this will result in $110 million in sales by 2021, which would increase 201 percent from the previous year. PacBio’s long-read sequencing technology is transforming how scientists can map genomes. Using long sections of DNA, the PacBio platform allows researchers to sequence an entire genome with high fidelity (HiFi). This whole-genome sequencing approach provides a cost-effective and accurate solution for characterizing previously unsequenced or “missing” genes that represent up to 8% of the total genomic content.

VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. NTLA’s lead in vivo product candidates are nex-z for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of HAE. NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the kallikrein B1 gene in the liver, with the goal of achieving lifelong control of HAE attacks after a single dose. Nex-z is an investigational CRISPR-based therapy designed to inactivate the TTR gene in liver cells, thereby preventing the production of TTR protein for the treatment of ATTR amyloidosis. CRISPR (clustered regularly interspaced short palindromic repeats) genome editing has been hyped for years. Major genomics breakthroughs — and potentially explosive growth for some stocks — could be on the way.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

What is the best CRISPR stock to buy?

Caribou Biosciences was founded in 2011 by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, University of Zurich biochemistry professor Martin Jinek, Johns Hopkins professor James Berger, and Rachel Haurwitz. Oxford Nanopore Technologies was founded in 2005 by scientists conducting research at the University of Oxford in England. Its focus from the beginning was on nanopore gene sequencing, where DNA is passed through a membrane with tiny holes called nanopores.

She believes the market is changing and that early adopters will benefit from the convergence of genomics and AI. According to Grand View Research, the global genomics market was estimated to be worth $32.65 billion in 2023 and is projected to grow at a compound annual growth rate of 16.5% between 2024 and 2030. The pharmaceutical and biotechnology companies segment dominated the global genomic market in 2023, as per the aforementioned research. In terms of market share, North America held the biggest share in 2023 (42.65%), while Asia Pacific is anticipated to develop at the fastest rate during the forecast period.

Best Genomics Stocks to Buy According to Hedge Funds

On September 24, Wave announced positive interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 being investigated in boys with Duchenne muscular dystrophy. The news led shares in the company to grow in price by more than 68 percent to close at US$9.01 on September 25. Beam Therapeutics utilizes CRISPR technology to replace specific bases in the genome utilizing a method known as base editing, which only breaks one DNA molecule and may enhance cell survival rates. Bank of America has given BEAM stock a “buy” rating and a $150 price target.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution. According to Musk, this technology could be worth $250 trillion by 2040. Oncodetect, which was created for molecular residual disease identification, has improved prognosis prediction over standard-of-care approaches in stage III colorectal cancer, as proven by both Alpha- and Beta-CORRECT trials. A laboratory technician using high tech equipment to sequence cancer genomics. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. These companies create drugs and treatments for some of the biggest medical problems of our time.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation. You simply won’t find another AI and energy stock this cheap… with this much upside. In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap. I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.